Skip to main navigation Skip to search Skip to main content

Rapcabtagene: A Phase 2, Adaptive, Randomized, Open-Label, Assessor-Blinded Active-Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel vs. SOC in Patients Suffering from Systemic Lupus Erythematosus (SLE) with Active, Refractor

Grants and Contracts Details

StatusActive
Effective start/end date11/8/24 → 12/21/30

Funding

  • Novartis (domestic): $150,417.00